新兴和新兴的药物和基因疗法用于弗里德里希心力衰竭
Varlli Scott1,2, Martin B Delatycki1,2,3, Geneieve Tai1
1Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
CNS drugs
|August 8, 2024
概括
弗里德里希衰竭 (FRDA) 疗法正在进步,临床试验中的新药和基因疗法正在进步. 奥马维洛克索隆 (Omaveloxolone) 是一种药物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 弗里德里希衰竭 (FRDA) 是一种缩短生命的神经退行性疾病.
- 目前的治疗方法旨在减缓疾病的进展.
研究的目的:
- 在临床试验中审查FRDA目前的药物和基因疗法.
- 讨论FRDA治疗开发中的挑战和进展.
主要方法:
- 审查正在进行的第一阶段临床试验及以后的情况.
- 治疗策略的分析,包括氧化应激减轻,线粒体功能改善,代谢途径调节和基因疗法.
主要成果:
- 奥马维洛克索隆是第一个批准用于FRDA (16岁以上) 的治疗方法.
- 在向治疗和基因编辑技术方面取得了重大科学进展.
- 由于患者人数较少,挑战仍然存在.
结论:
- 药物和基因疗法的进步为FRDA患者提供了新的希望.
- 敏感的结果测量和自然史数据对于治疗批准至关重要.
- 奥马维洛克索隆的批准标志着FRDA疗法中的一个重要里程碑.
相关概念视频
Gene Therapy
25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


